CVS HEALTH Corp Buys 10,000 Shares of iShares Biotechnology ETF $IBB

CVS HEALTH Corp purchased a new position in iShares Biotechnology ETF (NASDAQ:IBB) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 10,000 shares of the financial services provider’s stock, valued at approximately $2,105,000. iShares Biotechnology ETF accounts for approximately 0.5% of CVS HEALTH Corp’s portfolio, making the stock its 28th largest position.

Several other hedge funds also recently made changes to their positions in the stock. Ndwm LLC purchased a new stake in iShares Biotechnology ETF during the 3rd quarter worth about $1,459,000. Ritholtz Wealth Management purchased a new position in iShares Biotechnology ETF during the 3rd quarter valued at about $428,000. Joel Isaacson & Co. LLC grew its holdings in iShares Biotechnology ETF by 4.3% during the 3rd quarter. Joel Isaacson & Co. LLC now owns 2,916 shares of the financial services provider’s stock valued at $614,000 after buying an additional 120 shares in the last quarter. Jefferies Financial Group Inc. increased its position in shares of iShares Biotechnology ETF by 38.1% during the third quarter. Jefferies Financial Group Inc. now owns 417,500 shares of the financial services provider’s stock valued at $87,896,000 after buying an additional 115,194 shares during the period. Finally, Moneco Advisors LLC increased its position in shares of iShares Biotechnology ETF by 84.6% during the third quarter. Moneco Advisors LLC now owns 3,170 shares of the financial services provider’s stock valued at $667,000 after buying an additional 1,453 shares during the period. 62.45% of the stock is currently owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Price Performance

Shares of iShares Biotechnology ETF stock opened at $218.14 on Thursday. iShares Biotechnology ETF has a 12-month low of $159.68 and a 12-month high of $222.29. The company’s 50-day moving average price is $208.98 and its 200-day moving average price is $186.54.

iShares Biotechnology ETF Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 18th. Investors of record on Tuesday, September 15th were paid a dividend of $0.0112 per share. This is a decrease from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238. This represents a $0.04 annualized dividend and a yield of 0.0%. The ex-dividend date of this dividend was Tuesday, September 15th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.